PD-L1 Antikörper (AA 18-227)

Produktnummer ABIN5027432

Dieses Anti-PD-L1-Antikörper ist ein Kaninchen Polyklonal-Antikörper zur Detektion von PD-L1 in WB. Geeignet für Human.

Kurzübersicht für PD-L1 Antikörper (AA 18-227) (ABIN5027432)

Target: PD-L1 (CD274 (PD-L1))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser PD-L1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Produktdetails anti-PD-L1 Antikörper

Bindungsspezifität: AA 18-227

Aufreinigung: Protein A Chromatography

Immunogen: A partial length recombinant PDL1 protein (amino acids 18-227) was used as the immunogen for this antibody.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB: 2-4 μg/mL

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.5 mg/mL

Buffer: PBS containing 0.05 % BSA, PH 7.4

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store the antibody at 4°C, stable for 6 months. For long-term storage, store at -20°C. Avoid repeated freeze and thaw cycles.

Details zu PD-L1

Target: PD-L1 (CD274 (PD-L1))

Andere Bezeichnung: PD-L1 / CD274

Hintergrund: Programmed death ligand 1/PD-L1 (also called B7-H1 and CD274) is a T cell inhibitory molecule that is expressed on antigen presenting cells (APC) leading to T cell anergy and/or apoptosis upon ligation to its receptor Programmed death-1 (PD-1, CD279) on T cells. PD-L1 is expressed on tumor cells of a subset of breast cancer patients. It could also induce EMT and enhance RCC cell cancer stemness through up-regulation of SREBP-1c. Blocking the immunosuppressive PD-1/PD-L1 pathway has antitumor activity in multiple cancer types, and PD-L1 expression on tumor cells and infiltrating myeloid cells correlates with the likelihood of response.

Molekulargewicht: 33 kDa

Gen-ID: 29126

UniProt: Q9NZQ7

Pathways: Cancer Immune Checkpoints